Nickname | OMRF |
---|---|
Formation | 1946 |
Type | Nonprofit organization, independent research institution |
73-0580274 | |
Legal status | 501(c)3) Nonprofit Organization |
Purpose | Medical Research |
Headquarters | Oklahoma City, OK USA |
President | Andrew S. Weyrich, Ph.D. |
Budget | $92,338,587 USD |
Staff | 450 |
Website | omrf |
The Oklahoma Medical Research Foundation (OMRF), located in the Oklahoma Health Center in Oklahoma City, Oklahoma, is an independent, nonprofit biomedical research institute. Established in 1946, OMRF is dedicated to understanding and developing more effective treatments for human disease. Andrew S. Weyrich, Ph.D. serves as president of OMRF, [1] which employs more than 500 scientific and administrative staff members.
OMRF's scientists, who include a member of the National Academy of Sciences, hold more than 700 U.S. and international patents and have spun off 11 biotech companies. Discoveries at OMRF led to Xigris, the first FDA-approved drug for the treatment of severe sepsis, and Ceprotin, a therapy for people suffering from a rare and life-threatening blood disorder known as protein C deficiency. Research at OMRF also identified the enzyme believed responsible for Alzheimer's disease and laid the groundwork for OncoVue, [2] a breast cancer risk assessment test.
Beginning from discussions among the alumni of the University of Oklahoma Medical School in 1944, several doctors began to develop the idea of an independent research organization adjacent to - but separate from - the medical school. Led by Dr. Mark R. Everett, a Harvard Medical School grad who rose from professor to become dean of the OU Medical School in 1947, [3] they agreed on August 3, 1946, to incorporate as the Oklahoma Medical Research Foundation (OMRF), a private, nonprofit, independent research institution in Oklahoma City. In April 1947 Oklahoma's Governor, Roy J. Turner became general chair of a statewide fund drive for OMRF that spanned all 77 of Oklahoma's counties. By May 1949, 7,000 Oklahomans had donated and pledged $2.35 million, and construction of OMRF began.
The Foundation officially began operations on July 3, 1949. [4] Sir Alexander Fleming, the British scientist who discovered penicillin, made his first visit to the United States to give the keynote address at the dedication. An estimated 2,500 people attended the ceremonies, where Fleming pronounced the future "bright," even though the first building was at the time, in the Nobel laureate's words, "just a big hole in the ground.". [5] Dr. Edward C. Reifenstein Jr., became the foundation's first director.
OMRF opened the doors of its first building on Dec. 17, 1950. Since that time, OMRF has grown from 5 principal scientists to 50, and its staff has grown from roughly two dozen employees to almost 500. Securing more than $30 million annually in competitive research grants from the National Institutes of Health and other granting agencies, OMRF is a member of the Association of Independent Research Institutes. [6] Its scientists focus on research in the areas of immunology, cardiovascular biology and diseases of aging.
In 2000, Jordan J.N. Tang [7] and colleagues created an inhibitor that, in vitro, stopped the enzyme thought to cause Alzheimer's disease. The biotechnology company CoMentis [8] has since built on that discovery to create an experimental drug for the treatment of Alzheimer's. In 2007, Tang uncovered a molecular mechanism that links an Alzheimer's susceptibility gene (known as E4) to the process of disease onset. In OMRF's free radical biology and aging research program, Robert A. Floyd [9] leads a team of scientists who focus on the mechanisms that cause neurodegenerative diseases such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).
Technology developed in the laboratories of Eldon Jupe and Linda F. Thompson [10] led to the creation of a test for assessing breast cancer risk in women. Marketed as OncoVue, the test is produced by Intergenetics, Inc., [11] and available in clinics the U.S. Paul W. Kincade [12] leads a group of immunologists in the study of the causes of lymphomas, leukemias and myelomas. With a research-grade magnetic resonance imaging facility, OMRF scientists are developing methods of using MRI to speed the process of identifying and treating brain, liver and bladder cancers. In 2006, molecular biologist Gary J. Gorbsky [13] and his lab were the first to reverse the process of cell division, a discovery detailed in the journal Nature that may have implications for the prevention and treatment of cancer and birth defects.
Led by Rodger P. McEver [14] and Charles T. Esmon [15] OMRF's cardiovascular biology research program works to pinpoint the origins of cardiovascular disease. Esmon's research has led to the development of two FDA-approved drugs: Xigris, a treatment for severe sepsis (blood poisoning), and Ceprotin, a therapy for children suffering from life-threatening blood-clotting complications.
OMRF's largest research program is dedicated to the study and treatment of systemic lupus erythematosus and other autoimmune diseases. Led by physician-researchers Judith A. James [16] Robert Scofield [17] and Morris Reichlin [18] this group has identified antibodies that appear in the blood years before the clinical onset of lupus. They also are studying the role a common virus may play in triggering lupus. Their work led the National Institutes of Health to establish the Lupus Family Registry and Repository [19] at OMRF. The LFRR is a resource that scientists worldwide can use in their own lupus research. The collection includes DNA, sera, plasma, and data from systemic lupus patients, first degree relatives, and healthy volunteers. Study participation involves completing paperwork and donating a one-time blood sample.
In 1956, OMRF established its Sir Alexander Fleming Scholar Program, a summer research training program for Oklahoma high school and college students. [20] [21]
The 'Teen Leaders in Philanthropy' class was created in 2012 to let up to 40 high school sophomores, juniors and seniors develop hands-on leadership skills and an understanding of what a nonprofit organization does. The program gives participants a chance to learn from a variety of charitable organizations, donors and volunteers during nine sessions throughout the school year. [22] [23]
OMRF also provides the training ground for graduate and postdoctoral students each year in the M.D./Ph.D Program at the University of Oklahoma Medical School. [24]
OMRF maintains numerous core facilities, including:
OMRF is funded through grants and independent contributions. One of the more unusual contributions is a share in the royalties of the musical Oklahoma!. Oklahoma born playwright Lynn Riggs wrote the original play, "Green Grow The Lilacs," on which the musical was based. Upon his death, he willed his 1% royalty to his 4 siblings. When his brother William Edgar Riggs died, OMRF received rights to that one-quarter share. As of the end of 2018, it has generated over $700,000 in earnings. [33]
The Medical University of South Carolina (MUSC) is a public medical school in Charleston, South Carolina. It opened in 1824 as a small private college aimed at training physicians and has since established hospitals and medical facilities across the state. It is one of the oldest continually operating schools of medicine in the United States and the oldest in the Deep South.
SUNY Downstate Medical Center is a public medical school and hospital in Brooklyn, New York. It is the southernmost member of the State University of New York (SUNY) system and the only academic medical center for health education, research, and patient care serving Brooklyn's 2.5 million residents. As of Fall 2018, it had a total student body of 1,846 and approximately 8,000 faculty and staff.
The Medical Scientist Training Programs (MSTPs) are dual-degree training programs that streamline the education towards both clinical and research doctoral degrees. MSTPs are offered by some United States medical schools, who are awarded financial support from the National Institute of General Medical Sciences, a branch of the National Institutes of Health (NIH). The goal of these training programs is to produce physician scientists who can translate laboratory discoveries into effective treatments for patients.
The Eli and Edythe L. Broad Institute of MIT and Harvard, often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and it partners with the Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.
Leonard M. Miller School of Medicine (UMMSM) is the University of Miami's graduate medical school in Miami, Florida. Founded in 1952, it is the oldest medical school in the state of Florida.
The State University of New York Upstate Medical University is a public medical school in Syracuse, New York. Founded in 1834, Upstate is the 15th oldest medical school in the United States and is the only medical school in Central New York. The university is part of the State University of New York (SUNY) system.
Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focusing on basic and translational research, with major research programs in cancer, neurodegeneration, diabetes, infectious, inflammatory, and childhood diseases. The institute also specializes in stem cell research and drug discovery technologies.
Eva Lucille Feldman is an American physician-scientist who is a leading authority on neurodegenerative disease. She serves as the Russell N. DeJong Professor of Neurology at the University of Michigan, as well as Director of the NeuroNetwork for Emerging Therapies and ALS Center of Excellence at Michigan Medicine. She was also named the James W. Albers Distinguished University Professor of Neurology.
The Lupus Research Alliance (LRA) is an American voluntary health organization based in New York City whose mission is to find better treatments and ultimately prevent and cure systemic lupus erythematosus, a debilitating autoimmune disease, through supporting medical research. The organization was born from the merger of three organizations: the Lupus Research Institute (LRI) and the S.L.E. Lupus Foundation with the Alliance for Lupus Research (ALR), which was founded by Robert Wood "Woody" Johnson IV, a member of the Johnson & Johnson family and owner of the New York Jets. As of 2020 the LRA's cumulative research commitment was $220,000,000.
John Quinn Trojanowski was an American academic research neuroscientist specializing in neurodegeneration. He and his partner, Virginia Man-Yee Lee, MBA, Ph.D., are noted for identifying the roles of three proteins in neurodegenerative diseases: tau in Alzheimer's disease, alpha-synuclein in Parkinson's disease, and TDP-43 in Amyotrophic Lateral Sclerosis (ALS) and frontotemporal degeneration.
Michael D. Lockshin is an American professor and medical researcher. He is known for his work as a researcher of autoimmune diseases, with focus on antiphospholipid syndrome and lupus. He is Professor Emeritus of Medicine and the Director Emeritus of the Barbara Volcker Center for Women and Rheumatic Disease at Hospital for Special Surgery. He retired from HSS on January 31st, 2023.
Peter Henry St George-Hyslop, OC, FRS, FRSC, FRCPC, is a British and Canadian medical scientist, neurologist and molecular geneticist who is known for his research into neurodegenerative diseases. St George-Hyslop is one of the most cited authors in the field of Alzheimer's disease research. He has identified a number of key genes that are responsible for nerve cell degeneration and early-onset forms of Alzheimer's disease. These include the discovery of the presenilins, Nicastrin, and SORL1 genes. Presenilin mutations are the most common cause of familial Alzheimer's disease. St George-Hyslop also co-led the discovery of the gene for the amyloid precursor protein.
Gladstone Institutes is an independent, non-profit biomedical research organization whose focus is to better understand, prevent, treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer's disease. Its researchers study these diseases using techniques of basic and translational science. Another focus at Gladstone is building on the development of induced pluripotent stem cell technology by one of its investigators, 2012 Nobel Laureate Shinya Yamanaka, to improve drug discovery, personalized medicine and tissue regeneration.
The Max Planck Florida Institute for Neuroscience (MPFI), is a research facility located in Jupiter, Florida. Its research focuses on brain function and neural circuits, using techniques to visualize microscopic molecular processes. It is the first institute established by the Max Planck Society in North America.
Jonathan D. Wren is a scientific investigator at the Oklahoma Medical Research Foundation in the Department of Arthritis and Clinical Immunology, and an Adjunct Assistant Professor in the Department of Biochemistry and Molecular Biology at the University of Oklahoma Health Sciences Center.
The Foundation for the National Institutes of Health (FNIH) is a not-for-profit, 501(c)(3) charitable organization established by the US Congress in 1990. Located in North Bethesda, MD, the FNIH raises private-sector funds, and creates and manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH).
Mercè Boada y Rovira is a Catalan neurologist. She has dedicated her professional career to neurodegenerative diseases. More specifically, dementia and Alzheimer's disease. She was a co-founder of the ACE Foundation, a private non-profit entity dedicated to diagnosis, treatment, research, and helping people with Alzheimer's and their families. Boada received the "Creu de Sant Jordi", Catalonia's highest honor, in 2016.
Dennis J. Selkoe is an American physician (neurologist) known for his research into the molecular basis of Alzheimer's disease. In 1985 he became Co-Director of the Center for Neurological Diseases and from 1990, Vincent and Stella Coates Professor of Neurological Diseases at Harvard Medical School. He is also a Fellow of the AAAS and a member of the National Academy of Medicine.
Judith Ann James is an American rheumatologist. She first came to Oklahoma Medical Research Foundation (OMFR) as a Sir Alexander Fleming Scholar in the summer of 1988, and then joined the foundation’s scientific staff in 1994.
Karen Marie Winkfield is an American radiation oncologist, physician-scientist, and implementation scientist. She is the Ingram Professor of Cancer Research at Vanderbilt University School of Medicine.